Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
 free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 free
 free
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Prevention of the renarrowing of coronary arteries using drug-eluting stents in the perioperative period: an update Llau JV; Ferrandis R; Sierra P; Gomez-Luque AVasc Health Risk Manag 2010[Oct]; 6 (ä): 855-67The management of patients scheduled for surgery with a coronary stent, and receiving 1 or more antiplatelet drugs, has many controversies. The premature discontinuation of antiplatelet drugs substantially increases the risk of stent thrombosis (ST), myocardial infarction, and cardiac death, and surgery under an altered platelet function could also lead to an increased risk of bleeding in the perioperative period. Because of the conflict in the recommendations, this article reviews the current antiplatelet protocols after positioning a coronary stent, the evidence of increased risk of ST associated with the withdrawal of antiplatelet drugs and increased bleeding risk associated with its maintenance, the different perioperative antiplatelet protocols when patients are scheduled for surgery or need an urgent operation, and the therapeutic options if excessive bleeding occurs.|*Drug-Eluting Stents/adverse effects[MESH]|*Myocardial Revascularization/adverse effects/instrumentation/methods[MESH]|Aspirin/therapeutic use[MESH]|Blood Loss, Surgical/prevention & control[MESH]|Clopidogrel[MESH]|Coronary Thrombosis/prevention & control[MESH]|Coronary Vessels/drug effects/physiopathology/*surgery[MESH]|Humans[MESH]|Perioperative Care/methods[MESH]|Perioperative Period[MESH]|Piperazines/therapeutic use[MESH]|Platelet Aggregation Inhibitors/therapeutic use[MESH]|Prasugrel Hydrochloride[MESH]|Thiophenes/therapeutic use[MESH]|Ticlopidine/analogs & derivatives/therapeutic use[MESH] |
